Christopher B. Ehrlich - 09 Jun 2022 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2022, 18:39:50 UTC
Prior SEC filing: 22 Feb 2022
Next SEC filing: 27 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Byrnes, Attorney-in-Fact for Christopher B. Ehrlich

Key filing fact

Christopher B. Ehrlich filed Form 4 for eFFECTOR Therapeutics, Inc. on 13 Jun 2022.

Key facts

This page summarizes Christopher B. Ehrlich's Form 4 filing for eFFECTOR Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2022, 18:39.

Change

Previous filing in this sequence was filed on 22 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EFTR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 09 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $1.65
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest in full on the earlier to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.